(Q44692720)

5 December 2017

title

Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach (English)

1 reference

5 December 2017

2

1 reference

5 December 2017

Giancarlo Tirelli

1

1 reference

5 December 2017

Silvia Chiandussi

3

1 reference

5 December 2017

Franca Dore

4

1 reference

5 December 2017

Elena De Nardi

5

1 reference

5 December 2017

Roberto Di Lenarda

6

1 reference

5 December 2017

language of work or name

1 reference

1 September 2009

1 reference

5 December 2017

1 reference

5 December 2017

volume

31

1 reference

5 December 2017

issue

9

1 reference

5 December 2017

page(s)

1249-1254

1 reference

The pharmacology of bisphosphonates and new insights into their mechanisms of action

5 December 2017

cites work

1 reference

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

21 January 2018

1 reference

7 January 2021

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

7 January 2021

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

7 January 2021

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

1 reference

7 January 2021

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

7 January 2021

The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo.

1 reference

7 January 2021

Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo

1 reference

7 January 2021

Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

1 reference

7 January 2021

Bisphosphonates: mechanisms of action

1 reference

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

7 January 2021

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

1 reference

7 January 2021

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

1 reference

7 January 2021

Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases

1 reference

7 January 2021

Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy

1 reference

7 January 2021

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

7 January 2021

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

1 reference

7 January 2021

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

7 January 2021

Intravenous bisphosphonates and osteonecrosis

1 reference

7 January 2021

Identifiers

DOI

10.1002/HED.21019

1 reference

5 December 2017

1 reference